Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 13/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | MELK | Q14680 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30664181 | 0.88 | ROCK2 (0.41) | ROCK2KCNH2DYRK1AMAT2A | |
| SCHEMBL20122913 | 0.88 | ROCK2 (0.41) | ROCK2KCNH2DYRK1AMAT2A | |
| SCHEMBL20122763 | 0.87 | ROCK2 (0.45) | ROCK2KCNH2DYRK1A | |
| SCHEMBL30664343 | 0.87 | ROCK2 (0.45) | ROCK2KCNH2DYRK1A | |
| SCHEMBL20123017 | 0.86 | L3MBTL1 (0.43) | ROCK2KCNH2DYRK1ACCNCCDK8 | |
| SCHEMBL30664334 | 0.86 | L3MBTL1 (0.43) | ROCK2KCNH2DYRK1ACCNCCDK8 | |
| SCHEMBL30664226 | 0.84 | PDK2 (0.41) | ROCK2KCNH2DYRK1ACCNCCDK8 | |
| SCHEMBL20122996 | 0.84 | PDK2 (0.41) | ROCK2KCNH2DYRK1ACCNCCDK8 | |
| SCHEMBL30664198 | 0.83 | PDK2 (0.37) | ROCK2KCNH2MAT2A | |
| SCHEMBL20122929 | 0.83 | PDK2 (0.37) | ROCK2KCNH2MAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11130755-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2021-09-28 | — | — | US | disclosed |
| EP-3792262-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2021-03-17 | — | — | EP | disclosed |
| EP-3535263-B1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2020-09-30 | — | — | EP | disclosed |
| EP-3318563-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2018-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | GRM4 1792/4885ROCK2 1093/4885KCNH2 3028/4885 |
| US-11130755-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | GRM4 1792/4885ROCK2 1093/4885KCNH2 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.